ALXO Q2 2024 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$220,000

Operating Income

-$42M

Net Income

-$39M

EPS (Diluted)

$-0.76

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$215M

Total Liabilities

$55M

Stockholders' Equity

$159M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$220,000	$0	—
Operating Income	-$42M	-$37M	-12.9%
Net Income	-$39M	-$34M	-15.3%